INOVA Diagnostics Announces Launch of QUANTA Lite® Calprotectin to Aid in Diagnosis of Inflammatory Bowel Disease

SAN DIEGO, June 16, 2014 /PRNewswire/ -- INOVA Diagnostics Inc., a worldwide leader in autoimmune diagnostic reagents and systems for the clinical laboratory, is pleased to announce the global launch of QUANTA Lite Calprotectin, a new FDA cleared assay.  This important assay, which aids in the diagnosis of Inflammatory Bowel Disease (IBD), can also help differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other laboratory and clinical findings. 

The accurate detection of calprotectin levels in stool can provide critical information to physicians determining the appropriate care of millions of patients suffering from gastrointestinal disorders. QUANTA Lite Calprotectin is an FDA cleared, quantitative enzyme linked immunosorbent assay (ELISA) that detects calprotectin levels. 

The launch of the QUANTA Lite Calprotectin assay further expands the INOVA Diagnostics portfolio in the area of autoimmune gastrointestinal disorders.  According to Michael Mahler, PhD, Vice President of Research and Development for INOVA Diagnostics, "We are very pleased to launch this high performing assay to meet the increasing demand from laboratories worldwide.  Gastrointestinal pain is a common reason for seeking medical attention. Inaccurate diagnosis at the screening level can contribute to unnecessary procedures and increased healthcare costs. The QUANTA Lite Calprotectin assay can improve patient care while potentially reducing overall costs."

Roger Inglès, CEO of INOVA Diagnostics added "The benefits of fecal calprotectin testing are being recognized by healthcare systems around the world as evidenced by the recent recommendation from the National Institute for Health and Care Excellence (NICE) in the UK. As a worldwide leader in the autoimmunity in vitro diagnostics (IVD) market, INOVA Diagnostics is perfectly positioned to quickly increase awareness and adoption of this important new test across the globe."

Laboratories interested in the new QUANTA Lite Calprotectin assay may visit www.inovadx.com for more details.

About INOVA Diagnostics, Inc.
INOVA Diagnostics, Inc. is a privately held company headquartered in San Diego, California, and is part of Werfen Group, a global leader in IVD  with a long term commitment to providing high quality, innovative solutions for hospitals and clinical laboratories to enhance patient care. INOVA Diagnostics manufactures IVD systems and reagents for autoimmune disease that are used in clinical laboratories and hospitals around the world, and is a leader in the development and commercialization of new autoimmune technologies and diagnostic markers.  Further information about INOVA Diagnostics can be found at www.inovadx.com.

QUANTA Lite is a registered trademark of INOVA Diagnostics, Inc.

SOURCE INOVA Diagnostics Inc.